Article
Mutations conferring resistance to a hepatitis C virus (HCV) RNA-dependent RNA polymerase inhibitor alone or in combination with an HCV serine protease inhibitor in vitro.
Antimicrobial agents and chemotherapy - 1 Oct 2005
Mo Hongmei, Lu Liangjun, Pilot-Matias Tami, Pithawalla Ron, Mondal Rubina, Masse Sherie, Dekhtyar Tatyana, Ng Teresa, Koev Gennadiy, Stoll Vincent, Stewart Kent D, Pratt John, Donner Pam, Rockway Todd, Maring Clarence, Molla Akhteruzzaman
Abstract excerpt
Compounds A-782759 (an N-1-aza-4-hydroxyquinolone benzothiadiazine) and BILN-2061 are specific anti-hepatitis C virus (HCV) agents that inhibit the RNA-dependent RNA polymerase and the NS3 serine protease, respectively. Both compounds display potent activity against HCV replicons in tissue culture. In order to characterize the development of resistance to these anti-HCV agents, HCV subgenomic 1b-N replicon cells...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.